Complement C2

Complement C2 Overview

English NameComplement C2Approved Drugs0
Drugs in Clinical Trials1Target SynonymC3/C5 convertase
Highest Development StagePhase 3 Clinical
English NameComplement C2
Target SynonymC3/C5 convertase
Approved Drugs0
Drugs in Clinical Trials1
Highest Development StagePhase 3 Clinical

Complement C2 Background

C2 is a major histocompatibility complex class-III protein. Component C2 which is part of the classical pathway of the complement system is cleaved by activated factor C1 into two fragments: C2b and C2a. C2a, a serine protease, then combines with complement factor C4b to generate the C3 or C5 convertase. The lectin (LP) and classical (CP) pathways are two of the three main activation cascades of the complement system. These pathways start with recognition of different pathogen- or danger-associated molecular patterns and include identical steps of proteolytic activation of complement component C4, formation of the C3 proconvertase C4b2, followed by cleavage of complement component C2 within C4b2 resulting in the C3 convertase C4b2a.

Complement C2 Synonyms

C2,Complement C2,Complement Component C2

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
EmpasiprubartARGX-117Phase 3 ClinicalArgenx Se, Broteio Pharma BVCoronavirus Disease 2019 (COVID-19); Delayed Graft Function; Dermatomyositis; Motor Neuron Disease; Multifocal Motor Neuropathy; Myasthenia Gravis; Myositis; Polyneuropathies; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Details
  • Overview
  • Product List
  • Clinical Drug Information